Preclinical studies have shown positive effects of statins against specific cancers. This study aimed to determine the therapeutic effect of simvastatin in 12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer. Female albino mice were divided into two groups, with or without DMBA administration. After tumor appearance, DMBA-treated group was further divided into four groups (D1-D4) as control (D1), treated with simvastatin at 80 and 40 mg/kg/day, orally (D2 and D3) and tamoxifen (50 mg/kg/day, orally) treated group (D4). After 4 weeks, animals were sacrificed, serum samples were collected and tumors were dissected for histopathological study and determination of selected parameters. The tumor marker carcinoma antigen 15-3 (CA15-3), oxidative stress parameters and prostaglandin E2 (PGE2) levels were analyzed in serum and tumors in experimental groups. Tamoxifen and high dose of simvastatin improved parameters of mammary carcinogenesis including mean tumor volume, body weight and percent of mortality as compared to mice with breast tumors without treatment (D1). Additionally, simvastatin usage increased total antioxidant capacity (TAC) level, paraoxonase 1 (PON1) activity in serum and decreased total oxidant status (TOS) and malondialdehyde (MDA) levels in tumors similar to tamoxifen. No significant decrease was found in serum CA 15-3 and tumor PGE2 levels in simvastatin and tamoxifen treated groups as compared to D1 group. These data suggest that simvastatin has anticancer effects which are relatively similar to that of tamoxifen in an animal model of breast cancer.
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I N T R O D U C T I O N
Breast cancer poses a global health challenge and is currently considered as the most commonly encountered tumor in women worldwide [1] . According to available reports, 1 671 149 new cases of breast cancer were identified and 521 907 cases of deaths occurred due to breast cancer in the world in 2012 [2] . Different risk factors are associated with the development of breast cancer including gender, age, familial history, inherited genetic mutations, alcohol consumption, smoking, obesity and hormone exposure which is increased due to early menarche and late menopause [3] .
Animal models of chemically induced carcinogenesis are reliable and are routinely used to evaluate the diagnostic/therapeutic potential of candidate drugs in cancer investigations. In these models, changes in genomic structure occur in three stages including initiation, promotion and progression [4] . Chemical-induced carcinogenesis in rodents is particularly exploited in different cancer investigations due to its high similarity with human cancers with regard to histopathological features, step wise nature of tumor progression and activation of ras gene family members [5] . Polycyclic aromatic hydrocarbons (PAH) such as 7,12-dimethylbenz(a)anthracene (DMBA) with both carcinogenic and immunosuppressive effects (which is partly due to enhanced production of prostaglandin E2 (PGE2) have been successfully used to promote mammary tumors in rodent models [6] [7] [8] [9] [10] . To increase the chance of breast cancer induction, DMBA is administrated to young rodents, when mammary glands are undifferentiated and have high rate of cell proliferation [11] . Different mechanisms are proposed for DMBA carcinogenicity such as point mutation and activation of ras gene family, as well as disturbance in cellular oxidant-antioxidant balance [12] that has an important role in the development and progression of breast cancer [13] .
Therapeutic approaches for treatment of breast cancer include surgery, radiation and chemotherapy which are expensive and unfortunately inefficient in some cases where rates of cancer death remain to be high [14] . Tamoxifen is a commonly prescribed drug for reducing recurrence rate and increasing survival in estrogen receptor (ER)-positive breast cancers [15] . However, despite of its ability to kill the cancer cells, drug resistance in tumor cells is unavoidable [16] . In addition, hepatocellular damage, agranulocytosis [17] and development of different stages of nonalcoholic fatty liver disease [15] are reported side effects of tamoxifen in breast cancer patients.
On the other hand, DMBA-induced breast cancer is recognized as the earliest ER-positive mouse model, introduced by Medina et al., at 1980 [18] . In 2017, Alvardo et al., [19] clearly demonstrated that DMBAinduced mammary carcinomas were positive for both ER and progesterone receptor (PR), with a higher expression of ERa when compared to PR. The use of tamoxifen in this model of breast cancer is even older where the positive effect of tamoxifen in this regard was established in 1979 by Dix and Jordan [20] .
Finding new agents to be used alone or as an adjunct to other drugs in order to increase efficiency and minimize side effects is highly encouraged [21] . Statins as favorite lipid lowering drugs are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase enzyme, which is the rate limiting enzyme of cholesterol biosynthesis pathway and catalyzes the conversion of HMG-CoA to mevalonate. Among other beneficial effects, their anticancer properties and antioxidant activities are recently reported [21] [22] [23] [24] [25] [26] [27] [28] [29] . There are emerging evidence suggest that lipophilic statins have more pronounced anticancer effects than hydrophilic statins [21] . Besides, some studies have documented beneficial pleiotropic effects of statins including immunomodulatory role and antiinflammatory effects [30] , for example, by affecting PGE2 levels in serum and tissues [31, 32] .
Paraoxonase 1 (PON1) has a major role in the highdensity lipoprotein-mediated prevention of low-density lipoprotein oxidation and the metabolism of lipid-soluble radicals [33] . The association between polymorphisms in PON1 gene and breast cancer risk factors has been described previously [33, 34] , and the activity of this enzyme has been suggested as a marker of short-term death in breast cancer recurrence [35] . On the other hand, carcinoma antigen 15-3 (CA 15-3) is considered as a good marker to determine effectiveness of treatment as well as assessing the prognosis of the disease [36, 37] .
Another point that should be stated here is that upregulation of cyclooxygenase 2 (COX2) enzymes with resultant increase in PGE2 and ultimately estradiol production occurs in patients with breast cancer and COX2 overexpression is a significant unfavorable prognostic factor in Stage III breast cancer [38] .
Taken together, this study was conducted to evaluate the plausible therapeutic effect of simvastatin on DMBA-induced breast cancer with regard to tumor size, histopathological features and assay of serum and tumor antioxidant status, serum PON1 activity and CA 15-3 concentration as well as determination of PGE2 levels in serum and tumor tissue in comparison with tamoxifen.
M A T E R I A L S A N D M E T H O D S

Drugs
Simvastatin and tamoxifen were purchased from Osve and Iran Hormone Pharmaceutical companies (Tehran, Iran), respectively. Dimethylbenz(a)anthracene (DMBA) was purchased from Sigma Chemicals (St. Louis, USA).
Animals and study design
Sixty-seven healthy Swiss albino female 3 weeks old mice weighing 23.2 AE 0.91 g were purchased from Comparative and Experimental Medical Center, Shiraz, Iran. The animals were maintained in standard clean mice cages under standard laboratory conditions of room temperature (25 AE 2°C) and light (alternate 12-h light/dark cycles) throughout the experimental period. Mice had unlimited access to water and food and were weighed weekly. The experimental protocol was approved by the institutional Animal Ethical Committee of Shiraz University, School of Veterinary Medicine. After acclimatization, mice were divided randomly into two groups, Group I (C): mice only received sesame oil as vehicle by oral gavage (n = 7), representing the control group. Group-II (D): The remaining mice treated with 50 mg/kg of DMBA dissolved in sesame oil by oral gavages once a week for 4 weeks beginning at 5 weeks of age. The animals in group II were palpated weekly beginning 4 weeks after DMBA treatment up to the end of the experiment to detect early development of any abnormal mass and the basic parameters of mammary carcinogenesis including multiplicity (the median number of mammary tumors per mice), latency period (the first time of tumor appearance after the beginning of DMBA treatment) and the mean volumes of tumors were evaluated. Tumors volumes were calculated according to the formula V = (4/3) pR 1 2 R 2 (radius R 1 < R 2 ) [39] . It should be stated that palpation of breast tissue for finding DMBA-induced breast tumors is a routine and standard method for detection of tumoral tissue in this animal model and has been previously used by different authors for instance Minari and Okeke. [40] , Heffelfinger et al. [41] and Al-Ghananeem et al. [42] as a reliable method which could be reconfirmed by histopathological evaluation. Although some adjunct methods like thermography are suggested [43] , palpation and determination of tumor size are still the mainstays for detection of tumor formation. When tumor size reached 0.5 cm in the largest dimension (28 mice had this inclusion criterion), DMBA-treated group was randomly divided into four groups (n = 7 each) as follows: DMBA-treated control group (D1) without treatment, DMBA-treated mice receiving high dose (80 mg/kg/day) and low dose (40 mg/kg/day) of simvastatin for 1 month (respectively D2 and D3 groups) and DMBA-treated mice with daily administration of tamoxifen 50 mg/kg by oral gavages for 1 month (D4). Both simvastatin and tamoxifen were suspended in distilled water at the concentration of 14 mg/mL and 7 mg/mL (for 80 and 40 mg/kg of simvastatin, respectively), and 8.75 mg/ mL (for tamoxifen) freshly before administration and 0.2 mL of suspension was calculated to be administered to a 35-g mouse.
Tissues sample preparation and histopathological study At the end of the study, blood samples were collected by cardiac puncture under ether anesthesia and then the animals were sacrificed by decapitation. All mammary tumors and normal mammary glands of all groups were quickly dissected. For histological studies, half of the tumors were fixed in 10% formalin buffer, embedded in paraffin wax, and then stained with hematoxylin and eosin (H&E) and the other half of the tumors was immediately frozen in liquid nitrogen and stored in À70°C for biochemical assays.
Evaluation of oxidative stress markers Total oxidant status (TOS), total antioxidant capacity (TAC), and malondialdehyde (MDA) concentration were assayed in serum and mammary tumors. The tissue homogenate (10%) was prepared in phosphatebuffer solution (pH = 7.8) from mammary tissues and tumors and centrifuged at 4000 g for 20 min at 4°C. The supernatant was used to determine TOS, TAC, and MDA. TAC and TOS levels were measured by colorimetric methods using commercial kits (ZellBio, Ulm, Germany). MDA level in breast tissues and tumors was measured by using thiobarbituric acid (TBA) reagent, and absorbance was read in 535 nm according to the method of Peeri et al. [44] . Final concentration of MDA was calculated using its molar extinction coefficient (1. 56 9 10 5 cm/mmol) in equation A = ECL.
Determination of PON1 activity Serum samples were used for evaluation of PON1 activity using a commercial kit (ZellBio, Ulm, Germany). Paraoxon as the substrate of enzyme was used in this method. Enzyme hydrolysis of substrate produced yellow color with the intensity measured colorimetrically at 0 and 2 min in 412 nm wavelength. Enzyme activity was calculated according the following formula: enzyme activity (U/mL) = ΔOD/0.000848.
Assessment of tumor marker CA15-3
Serum CA15-3 tumor marker level was measured by a commercial kit (Bioassay Technology Laboratory, China). The kit used ELISA method based on biotin double antibody sandwich technology to assay mouse carbohydrate antigen 15-3 (CA15-3). Assay was performed following the procedure mentioned in the kit. Serum CA15-3 concentration was expressed as lIU/mL. Determination of PGE2 levels in tumors and mammary tissues Tissue homogenate from tumors and mammary glands was used for determination of PGE2 levels by sandwich ELISA as described by the kit manufacturer (Bioassay Technology Laboratory, China). The color intensity of the samples was read using an ELISA reader and 450 nm wavelength. After that, according to standard curve, tissue values of PGE2 were determined.
Statistical analysis
All values were expressed as the mean AE standard deviations. One-way ANOVA was used for statistical analysis using the statistical software SPSS 16.0 followed by Tukey's multiple comparison test. Also paired-samples t test was used for comparison of tumor volumes before and after treatment in groups. Differences with P-values <0.05 were considered significant.
R E S U L T S
Body weights, mortality, tumor parameters, and histopathological features of tumors The effect of simvastatin and tamoxifen on the body weights of all experimental groups (mean AE standard deviation) during 4 weeks of treatment is shown in Table I . The mean body weight in group C showed 8.82% increase at the end of the study as compared to the first week of treatment. In other groups, percent of increases were 5.56 and 5.41 in D2 and D3 groups, respectively. But in D1 and D4 groups, the mean body weight decreased 5.16% and 2.11%, respectively. However, differences in body weights among groups were not significant. All mice in normal group (C) lived up to the end of study. But percent of mortality in DMBAtreated mice were 10, 2.5, 0, and 2.5 in D1 to D4 groups, respectively. Breast tumors were observed only in DMBA-treated animals (D groups) in the thoracic and abdominoinguinal regions. Tumors were developed beginning 4 weeks after the final dose of DMBA. The mean of latency period was 80.4 AE 17.6 days from the final dose of DMBA for 60% of mice in DMBA-treated groups. The multiplicity was evaluated 1.8 tumors per mouse for all groups.
Volume of tumors was measured before and after treatment with simvastatin and tamoxifen in mice with induced breast tumors during 4 weeks (Figure 1) The results showed that volume of tumors in D1 and D3 groups significantly increased after treatment compared to before treatment. Volume increases (ratio of final to initial volumes) in D1 to D4 groups were 3.78, 2.70, 5.11, and 1.63 respectively. The H&E stained sections of the tumors were analyzed blindly by a specialist in the field of breast cancer histopathology. Table II shows the results obtained from Therapeutic effect of simvastatin on DMBA-induced breast cancer histopathological evaluation. Breast tumors were classified into four subtypes, adenocarcinoma (about 17.6%), adenosquamous carcinoma (11.8%), squamous cell carcinoma (64.7%), papillary carcinoma (5.9%), and all of the tumors were malignant. In D1 group, the histopathological feature of most tumors was squamous cell carcinoma. Microscopic examination of D1 slides showed severe necrosis and many mitotic figures with the high nuclear pleomorphism of tumor cells (Figure 2a) . The most tumors in D2 group that was treated with high dose of simvastatin were grade 2 of adenocarcinoma with moderate mitotic figures and pleomorphic nuclei (Figure 2b) . In tamoxifen-treated group (D4), most of the tumors were adenosquamous cell carcinoma and squamous cell carcinoma. Also, formation of keratin pearl was typical feature of the tumors (Figure 2c) .
Oxidative stress markers in mammary glands and tumors TAC, TOS, and MDA levels of tumors and mammary glands were evaluated in all experimental groups as oxidative stress markers (Table III) . TOS and MDA levels were significantly increased in D1 group as compared to other groups. Both of them decreased in treatment groups as compared to D1 group. So that, TOS levels was normalized in tumors of D4 group. Although TAC level increased in D2 group in comparison wuth other groups; its change and other differences between groups were not significant statistically.
Total antioxidant capacity and PON1 activity in serum TAC and PON1 activity were evaluated in the serum of all groups (Table IV) . The results showed that there was not any significant difference in PON1 activity between C and D1 groups. But its activity significantly increased in D2 and D4 groups as compared to other groups. Also TAC levels significantly increased in D2 group in comparison with other groups. Differences in TAC levels of other groups were not significant.
Serum CA 15-3 level
Serum levels of CA 15-3 in all experimental groups are shown in Figure 3 . Its level significantly increased in D1 group compared to C group (normal mice). But simvastatin and tamoxifen treatment in DMBA-induced breast cancer did not affect CA 15-3 level significantly as compared to D1 group.
PGE2 levels in mammary glands and tumors PGE2 levels were measured in tumors and mammary glands (Figure 4) . DMBA induced elevation in PGE2 Therapeutic effect of simvastatin on DMBA-induced breast cancer levels of tumors as compared to normal mammary glands. But both drugs had no effect on the level of this prostaglandin in comparison with D1 group.
D I S C U S S I O N
The present study investigates therapeutic potential of simvastatin in a chemical-induced breast cancer animal model in comparison with the routinely prescribed therapeutic agent tamoxifen and evaluates the plausible mechanisms that may have a role in this regard.
As the first finding of our study, we observed reduced mortality of mice treated with simvastatin accompanied by a relatively improved feature in histopathological evaluation as compared to D1 group, although tamoxifen showed a better outcome especially with regard to tumor size. Chemopreventive effects of statins against mammary carcinogenesis have been shown previously [25, 26, 45] , however; as far as we know, this is the first time that therapeutic effects of an statin in chemical-induced in vivo model of breast cancer are described. By observing the positive effects of simvastatin, we became very eager to clarify the possible mechanism(s) which could be involved in its effects. To this end, we evaluated the effects of simvastatin on oxidative stress markers of serum and tumor tissue as a plausible mechanism. It has been well established that during oxidative stress, the breast tumor stroma releases high energy nutrients that fuel cancer cells and facilitate their growth and survival in a way that breast cancer progression is dependent upon oxidative stress activated stroma. Therefore, targeting oxidative stress proposes potential new therapeutic approaches [13] . Consistent with previous studies [46, 47] , we observed an overt oxidative stress status in mice of D1 group demonstrated as increased MDA and TOS in tumor tissue. Administration of simvastatin especially at its higher dose as well as tamoxifen decreased the severity of oxidative stress. Interestingly, similar to tamoxifen, administration of simvastatin was associated with an increase in PON1 activity in serum of mice of D2 group. Consistent with this finding, Sozer et al. [48] showed that atorvastatin can increase PON1 activity in hypercholesterolemic rabbits, the same effect has also been shown in dyslipidemic patients [49] . Although we did not evaluate the mechanism for the increase in PON1 activity in our study, it has been shown that simvastatin can modulate gene expression of this enzyme [50] . Recent studies report a decrease in serum PON1 activity in breast cancer patients [51, 52] , and it has been suggested that serum PON1 concentration could be an efficient prognostic biomarker for the success of radiotherapy in patients with breast cancer [53] ; therefore, it seems that the ability of simvastatin in increasing PON1 activity may help in its therapeutic effect on chemicalinduced breast cancer, as observed in our study.
Tumor markers are recognized as substances produced by tumor cells and are present especially in blood or urine. Cancer antigen CA15-3, a biomarker of breast cancer, used routinely for surveillance purpose and assessment of treatment response [54, 55] . In the present study, serum CA15-3 levels significantly increased in D1 group compared to normal group (C). But in simvastatin-and tamoxifen-treated groups, no significant change was detected as compared to D1 group (Figure 3) . It may be due to the short duration of treatment period, because downward trend was observed in the level of CA15-3 in treated groups.
Different mechanisms are described for the mechanism behind the encouraging role of PGE2 in breast cancer progression like inactivation of host anti-tumor immune cells, stimulation of tumor cell migration, invasiveness, induction of stem-like cells, tumor-associated angiogenesis, and lymphangiogenesis [56] . Moreover, it has been shown that PGE2 can increase gene expression and activity of aromatase with resultant increase in estrogen production [57] . Our results on PGE2 levels in tumors and mammary glands showed the significant elevation of its level in D1 tumors as compared to normal mammary glands. It may be due to immunosuppressive and carcinogenic effects of DMBA [10] ; however, the differences in PGE2 levels of treated groups as compared to D1 group were not significant, although a tendency to decrease was observed in D2 and D4 groups (Figure 4) . Consistent with our results, in a study by Stamford et al. [58] , tamoxifen showed little effect on PGE2 levels of tumor tissue in mice, which was acclaimed to be due to weak inhibition of cyclooxygenase by the drug. Effect of statins on PGE2 levels has been inconsistent, for instance although statin treatment of microglial-like cells (In vitro) significantly reduced PGE2 levels [59] , lovastatin and simvastatin treatment on K-ras mutated human bronchial epithelial cells (HBECs) has increased PGE2 production [60] . An explanation for the trivial change that was observed in PGE2 level of tumor tissue in our study may be the relatively short period of treatment, although this needs to be further investigated. Furthermore, it seems that combination of simvastatin with a cyclooxygenase inhibitor may have more effective anticancer properties.
C O N C L U S I O N
The results of the present study provide new useful information about therapeutic efficacy of simvastatin in DMBA-induced mammary carcinogenesis in mice. Antioxidant potential of simvastatin could have a major role in this regard. Further studies are needed to elucidate other mechanisms of simvastatin.
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